UBS analyst Michael Yee reiterated a Buy rating and $175.00 price target on Gilead Sciences (NASDAQ: GILD).

The analyst commented, "Yeztugo monthly sales data was released yesterday - showing Yeztugo February sales up 56% m/m and with $100M in sales among both Jan and Feb (see chart). Implied scripts for March are trending around $58M so we think GILD should likely hit consensus of ~$145M. While there is variability among weekly scripts, IMS sales data seems to be tracking ~ 90% capture rate since the launch so we believe this is a better measure for tracking Yeztugo in the early days of the launch. We also think this is tracking nicely vs Apretude sales which was only up 7% m/m and potentially suggesting some early signs of pts preferring Q6M Yeztugo to Q2M Apretude - though we acknowledge monthly sales data for Apretude does seem to be more variable m/m."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $136.34 yesterday.